September 22.2008Preliminary Results for the year ended 30 June 2008 ...read more
Other news stories - Pivotal Phase III Pollinex® Quattro Ragweed study meets primary efficacy endpoint - Pollinex® Quattro data presented at European Academy of Allergology and Clinical Immunology meeting - Pivotal Phase III Pollinex® Quattro grass study meets primary efficacy endpoint - Interim Results - Allergy Therapeutics plc AGM resolutions passed
View all news
Allergy Therapeutics, Dominion Way, Worthing, West Sussex, BN14 8SA, United Kingdom
Tel +44 (0)1903 844 700
Click here to contact Allergy Therapeutics
View all images
